Search for European Projects

8 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis (FOLSMART)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), a first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked agains ...
Read Project

 8

 FINISHED 

Functional materials for fast diagnosis of wound infection (InFact)

Start date: Jan 1, 2014, End date: Dec 31, 2017,

"Early detection of an incipient wound infection is a challenge for the attending physician , since its early diagnosis allows the timely initiation of treatment, thus reducing the severity of the disease . Currently, however, wound infection is not diagnosed until becoming already evident. As a consequence, the treatment of the patient is further complicated and more likely to have a negative ou ...
Read Project

 11

 FINISHED 

Tumor Infiltrating Myeloid Cell Compartment (TIMCC)

Start date: Nov 1, 2012, End date: Oct 31, 2016,

"The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally c ...
Read Project

 8

 FINISHED 

Prolonged inhibition of semaphorine3a pathway via a bio-degradable implant towards a better therapy for visual sensory impairments (VISION)

Start date: Sep 1, 2012, End date: Aug 31, 2016,

"The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative. Acute optic nerve injury, ischemic optic neuropathy and glaucoma are conditions that initially lead to partial blindness and eventually could lead to total blindness. Extensive neuron and retinal ganglion cells (RGC) death is evidenced in these pathologies. Semaphorin 3A (Sema3A) is a cell sec ...
Read Project

 5

 FINISHED 

Novel approaches for prevention and degeneration of pathogenic bacteria biofilms formed on medical devices e.g. catheters (NOVO)

Start date: Jan 1, 2012, End date: Dec 31, 2014,

"Biofilms are bacterial communities encased in a self-produced hydrated polymeric matrix. An important characteristic of microbial biofilms is their innate resistance to the immune system and susceptibility to antibiotics. This resistance has made microbial biofilms a common cause of medical infections, and difficult-to-treat infections caused by colonized foreign bodies.The NOVO project aims at d ...
Read Project

 12

 FINISHED 

Folate-based nanobiodevices for integrated diagnosis/therapy targeting chronic inflammatory diseases (NANOFOL)

Start date: Dec 1, 2009, End date: Nov 30, 2013,

"NANOFOL proposes to develop a new diagnostic/therapy approach using folate based nanobiodevices (FBN) able to provide a new type of cost efficient treatment for chronic inflammatory diseases such as Atherosclerosis and Rheumatoid Arthritis with low side effects that will constitute a more advantageous solution than current therapies. NANOFOL will achieve all that by fulfilling the following obje ...
Read Project

 14

 FINISHED 

Selected peptides as drug candidates directed to pain and neurodegeneration (PEP2BRAIN)

Start date: Mar 1, 2009, End date: Feb 28, 2013,

...nd ADME/toxicity characteristics for our lead molecule. This requires technology, knowledge and innovation transfer since the inventors and Bioalvo are unable to perform this endeavour on their own. Synovo, a German company expert in ADME/tox tests and the University of Tuebingen, with a group expert in Medicinal Chemistry, joined Bioalvo and the Universities of Lisbon and Girona to transfer all ...
Read Project

 5

 FINISHED 

Novel anti-inflammatory compounds for autoimmune diseases (KINACEPT)

Start date: Dec 1, 2008, End date: Nov 30, 2010,

"The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition ...
Read Project

 10